Alkermes plc
Alkermes plc (ALKS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ALKS · as of Jun 8, 2026
Key Statistics
Explore Alkermes plc Data
alks stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 28 · Buy rate: 53.6%
The ALKS analyst consensus is Buy, based on ratings from 28 Wall Street analysts over the past 3 months. The average 12-month price target is $46.00, representing +7.48% upside from the current price of $42.80.
Competitors & Peers
alks competitorsALKS
ACAD
ACLX
AKRO
ARWR
CRSPStock Performance
Full HistoryAbout Alkermes plc
Alkermes plc a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States…
what is alkermes plc · alks stock overview · alkermes plc company profile · who is alkermes plc ceo · alks NASDAQ · alkermes plc headquarters · alkermes plc business segments
About Stock Overview & Key Data
Alkermes plc (ALKS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 16, 1991. As of the latest trading session, ALKS stock price is $42.80, with a market capitalization of $7.1B. The stock has returned +37.44% over the past 12 months and +52.97% year-to-date.
According to 28 Wall Street analysts, the consensus rating for Alkermes plc stock is Buy, with an average 12-month price target of $46.00. In fiscal year 2025, Alkermes plc reported revenue of $1.5B and net income of $241.7M. For detailed data — including Alkermes plc revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Alkermes plc (ALKS) stock price is $42.80. The stock is traded on NASDAQ under the ticker symbol ALKS. The 52-week range is $25.17 – $43.69.